Mutation Clinical Trials in Toronto, Ontario (12 Recruiting)

Showing 1–12 of 12 trials

Recruiting

Phase 1

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Solid TumorsNSCLCEGFR Exon 20 Insertion Mutations+1 more

ORIC Pharmaceuticals76 enrolled4 locationsNCT06816992

Recruiting

Phase 2

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Solid TumorsHER2 Mutation

Bayer111 enrolled54 locationsNCT06760819

Recruiting

Phase 3

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more

Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199

Recruiting

Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

PIK3CA Mutation

Relay Therapeutics, Inc.540 enrolled120 locationsNCT06982521

Recruiting

Phase 3

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

Servier Bio-Innovation LLC136 enrolled114 locationsNCT06127407

Recruiting

Phase 2Phase 3

Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

PALB2 Gene MutationPancreatic Cancer, Advanced or MetastaticBRCA1/2 Mutation

University Health Network, Toronto10 enrolled1 locationNCT06783140

Recruiting

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

CancerCancer, Therapy-RelatedRas (Kras or Nras) Gene Mutation+7 more

University Health Network, Toronto5,500 enrolled27 locationsNCT04151342

Recruiting

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Breast CancerOvarian CancerLung Cancer+15 more

University Health Network, Toronto2,500 enrolled1 locationNCT03702309

Recruiting

Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more

Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753

Recruiting

Mutation Clinical Trials in Toronto, Ontario

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Study of Olutasidenib and Temozolomide in HGG

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors